Here's what I actually said. But, details are not important in Cynata-land.
Now, it hasn't been stated that the enrolment for the FDA P2 trial has occurred in the USA. Westmead was first to be listed - it has had the greatest/longest opportunity to enroll a candidate. Add to that, that if they had of enrolled in the USA, they would of said so, clearly.
Note: My point was (and still is) that BIG dollars are needed. CYP has a shyte load less cash now then they did (refer my post quoted above). It is less likely now than it was then.
I'm reading the assurances from management that they have enough cash to do the trial. We will see. Costs are now accumulating in earnest.
Time will tell.
CYP Price at posting:
21.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)